Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Janssen Files TAR-200 in Japan for High-Risk Bladder Cancer
September 9, 2025
- Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
- GSK Recalls 7 Lots of Omjjara in Japan over Quality Issue
September 9, 2025
- Takeda Nabs Label Expansion for VWD Drug Vonvendi in US
September 9, 2025
- Talvey Seen as Promising Option for Hard-to-Treat Multiple Myeloma: Oncologist
September 8, 2025
- KM Biologics Developing Higher-Yield Liquid Immunoglobulin to Boost Efficiency and Supply
September 8, 2025
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
- Kaken’s Onychomycosis Drug Grabs German Approval
September 8, 2025
- Japan Ethical Drug Sales Inch Up 0.7% in July: Crecon
September 8, 2025
- Nichi-Iko Shows Signs of Recovery but Restructuring Still Underway: CEO
September 5, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- New Study of Vasomune-Partnered AV-001 Cleared in Canada: AnGes
September 5, 2025
- Keytruda Top-Selling Drug in Japan for 23 Months Running: Encise
September 5, 2025
- Eisai Begins FDA Rolling Submission for Leqembi SC for Starting Dose
September 4, 2025
- FDA Accepts Xocova NDA for COVID Post-Exposure Prophylaxis
September 4, 2025
- Bayer Pushes Cross-Border Open Innovation with New Co.Lab Connect Program
September 4, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
- Mitsubishi Tanabe Releases OD Tablet Form of Canalia in Japan
September 3, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…